Sutro Biopharma: Focused on developing next generation antibody drug conjugates (ADCs) and multi-specific antibody-based therapeutics for cancer therapy. The company’s discovery and development efforts are driven by its scalable cell-free protein expression platform (Xpress CF) that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro has three wholly-owned ADCs that are on clinical pathways and three high value collaborations with BMS, Merck, and EMD Serono. STRO-001, anti-CD74 ADC, for multiple myeloma and lymphomas is in Phase 1 and showed encouraging initial safety data at EHA & ASH 2019 – additional NHL cohort data will be presented at ASH 2020 and a dose expansion of Ph 1 expected to begin enrolling 1H21. STRO-002 for ovarian and endometrial cancer is also in a Phase 1 trial. At the AACR-NCI-EORTC conference in October 2019, STRO-002 data showed it was well tolerated and demonstrated it’s clinically efficacious at multiple doses (starting at 2.9 mg/kg). Additional Phase 1 data expected during a KOL in 4Q20 and dose-expansion of Ph 1 trial is expected to begin enrolling in 4Q20.